Prosecution Insights
Last updated: July 17, 2026
Application No. 19/076,820

Liquid-crystal medium

Non-Final OA §112
Filed
Mar 11, 2025
Priority
Mar 11, 2024 — CN PCT/CN2024/080938
Examiner
VISCONTI, GERALDINA
Art Unit
1737
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Merck Patent GmbH
OA Round
3 (Non-Final)
87%
Grant Probability
Favorable
3-4
OA Rounds
10m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 87% — above average
87%
Career Allowance Rate
1159 granted / 1339 resolved
+21.6% vs TC avg
Minimal +1% lift
Without
With
+1.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
29 currently pending
Career history
1372
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
29.2%
-10.8% vs TC avg
§102
30.9%
-9.1% vs TC avg
§112
17.2%
-22.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1339 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This office action is responsive to the Request for Continued Examination filed 17 April 2026, whereby the Amendment and Remarks filed 10 April 2026 was entered. Claims 1-16 remain pending and presently under consideration in this application. Response to Amendment Applicants have amended the base independent claim 1 as follows and argue that said amendment sufficiently distinguishes the liquid crystal composition of the present claims from that of the prior art of record: PNG media_image1.png 339 828 media_image1.png Greyscale PNG media_image2.png 329 809 media_image2.png Greyscale . The rejection of claims under 35 U.S.C. 102(a)(1) over each of Poetsch et al. (DE 102 17 771 A1), Kubo et al. (‘872), and Kato et al. (‘820), as respectively set forth in paragraphs 9-11 of the previous FINAL office action on the merits, are subsequently withdrawn. The rejection of claims under 35 U.S.C. 103 over each of Kubo et al. (‘872) and Kato et al. (‘820), as set forth in paragraph 13 of the previous FINAL office action on the merits, is likewise subsequently withdrawn. Response to Arguments Applicant’s arguments filed 10 April 2026 with respect to the alleged allowability of claims 1-16 have been considered but are moot because the amendment to claim 1 introduces a new issue under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as follows. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Amended claims 1 and 16 are rejected as being vague and indefinite when they each recite “wherein, for formulae BC and PH-1, H can be replaced by Deuterium” (emphasis added) in the ultimate line; the scope of the protection sought is not clear, as the claims fail to particularly point out and distinctly claim the antecedent basis for hydrogens in formulae BC and PH-1 which can be replaced by deuterium. Amended claim 3 is rejected as being vague and indefinite when it recites “wherein H can be replaced by Deuterium” (emphasis added) in the ultimate line; the scope of the protection sought is not clear, as the claim fails to particularly point out and distinctly claim the antecedent basis for hydrogens in formulae III and IIIA which can be replaced by deuterium. Amended claim 4 is rejected as being vague and indefinite when it recites “wherein H can be replaced by Deuterium” (emphasis added) in the ultimate line; the scope of the protection sought is not clear, as the claim fails to particularly point out and distinctly claim the antecedent basis for hydrogens in formulae III-1, III-6, and IIIA-1 which can be replaced by deuterium. Allowable Subject Matter Claims 1 and 16 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. Claims 3 and 4 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. Claims 2 and 5-15 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Geraldina Visconti whose telephone number is (571)272-1334. The examiner can normally be reached Monday-Friday, 8:00am-4:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mark F Huff can be reached at 571-272-1385. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. GERALDINA VISCONTI Primary Examiner Art Unit 1737 /GERALDINA VISCONTI/Primary Examiner, Art Unit 1737
Read full office action

Prosecution Timeline

Mar 11, 2025
Application Filed
Oct 20, 2025
Non-Final Rejection mailed — §112
Jan 16, 2026
Response Filed
Feb 13, 2026
Final Rejection mailed — §112
Apr 10, 2026
Response after Non-Final Action
Apr 17, 2026
Request for Continued Examination
Apr 20, 2026
Response after Non-Final Action
May 21, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12680024
LIQUID CRYSTAL DEVICE
4y 0m to grant Granted Jul 14, 2026
Patent 12674098
LIQUID-CRYSTAL MEDIUM
1y 4m to grant Granted Jul 07, 2026
Patent 12668743
Nonlinear Optical Chromophores Having Tetrahydrocarbazole Donor Groups, Lyotropic Compositions Containing the Same, and Methods of Poling Such Compositions
1y 7m to grant Granted Jun 30, 2026
Patent 12662632
LIQUID-CRYSTAL MEDIA AND PNLC LIGHT MODULATION ELEMENT
4y 3m to grant Granted Jun 23, 2026
Patent 12662630
LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE
1y 0m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
87%
Grant Probability
88%
With Interview (+1.4%)
2y 2m (~10m remaining)
Median Time to Grant
High
PTA Risk
Based on 1339 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month